Manganese produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this Parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism. Animal experiments have given the opportunity to examine the consequences of manganese overexposure under controlled conditions.
Manganese(II) oxide Manganese(II) oxide Manganese(II) oxide is an inorganic compound with chemical formula MnO. It forms green crystals. The compound is produced on a large scale as a component of fertilizers and food additives. Like many monoxides, MnO adopts the rock salt structure, where cations and anions are both octahedrally coordinated. Also like many oxides, manganese(II) oxide is often nonstoichiometric: its composition can vary from MnO to MnO. Below 118 K MnO is antiferromagnetic. MnO has the distinction of being one of the first compounds to have its magnetic structure determined by neutron diffraction, the report appearing in 1951. This study showed